Top 5 US Stock Gainers/Losers (>100B) (9.23)
Tesla(TSLA) rose 4.93%, with a trading turnover 21.5 Billion USD, and a year-to-date rose 0.6%. Micron Tech(MU) rose 2.94%, with a trading turnover 2.2 Billion USD, and a year-to-date rose 9.9%. Regeneron Pharma(REGN) fell 4.63%, with a trading turnover 1.3 Billion USD, and a year-to-date rose 24.3%. Novo Nordisk AS(NVO) fell 2.99%, with a trading turnover 875.4 Million USD, and a year-to-date rose 20.9%.
The Nasdaq Composite Index rose by 0.14%, with a year-to-date increase of 19.7%; the S&P 500 Index rose by 0.28%, with a year-to-date increase of 19.9%; and the Dow Jones Index rose by 0.15%, with a year-to-date increase of 11.8%.
Tesla (TSLA) rose by 4.93%, with a trading volume of $21.5 billion, and a year-to-date increase of 0.6%.
Barclays analysts expect Tesla's third-quarter deliveries to exceed market expectations due to a rebound in sales in the Chinese market. Additionally, the upcoming launch of Robotaxi next month could drive the stock price higher.
Micron Technology (MU) rose by 2.94%, with a trading volume of $2.18 billion, and a year-to-date increase of 9.9%.
CFRA analyst Angelo Zino maintained a buy rating for Micron Technology but lowered the target price from $170 to $140.
Regeneron Pharmaceuticals (REGN) fell by 4.63%, with a trading volume of $1.29 billion, and a year-to-date increase of 24.3%.
Analysts believe the market's reaction to the federal judge's rejection of the injunction and the nearly 5% drop is an overreaction. Regeneron's (REGN) underappreciated pipeline of prospective drug candidates can mitigate the impact of the court ruling, which rejected efforts to keep Amgen's Eylea biosimilar off the market. Although Eylea biosimilars have been approved, Regeneron has successfully blocked their sales, and the Eylea patent is set to expire in June 2027. Truist analysts maintained a buy recommendation and a $1,200 price target for Regeneron.
Novo Nordisk (NVO) fell by 2.99%, with a trading volume of $880 million, and a year-to-date increase of 20.9%.
Due to the massive sales generated by semaglutide approaching Novo Nordisk's entire R&D budget over the past 30 years, the company may struggle to defend the high prices of its drugs in a U.S. congressional hearing.
According to information on the U.S. Senate website, the Senate Committee on Health, Education, Labor, and Pensions is scheduled to hold a hearing at 10:00 AM local time on Tuesday, September 24. The theme of the hearing is "Why does Novo Nordisk charge American diabetes and obesity patients high prices for Ozempic and Wegovy?"
